BTK-selective covalent kinase inhibitor
Ph. I completed in HV, in Ph. II
SBDD from reversible BTK inhibitor and opt.
J. Med. Chem., Mar. 4, 2020
Novartis, Basel, CH
Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)